Isomorphic Labs, a drug discovery company under the umbrella of Google’s parent group Alphabet (NASDAQ: GOOGL), has entered into its inaugural pharmaceutical collaborations, signing separate agreements with Eli Lilly (NYSE: LLY) and Novartis (NYSE: NVS). These partnerships are aimed at discovering small-molecule therapeutics for multiple undisclosed targets.
Under the terms with Lilly, Isomorphic Labs will receive an upfront payment of USD 45 million, with the potential for up to USD 1.7 billion in milestone payments and sales royalties. Novartis, on the other hand, will provide an initial payment of USD 37.5 million, along with the possibility of up to USD 1.2 billion in milestone payments and sales royalties.
Isomorphic Labs will bring to the table its advanced computing capabilities and rational drug design AI models, which are designed to decipher the biological mechanisms of drug targets, create novel molecular structures, and predict the performance of drug candidates.- Flcube.com
